BCIQ Profiles

Company Profile Report

Meissa to bring synthetic RSV vaccine to clinic with $30M series A

With preclinical data in hand and manufacturing capabilities established, Meissa raised $30 million in a series A from new investor Morningside Ventures to bring its synthetic biology-based universal RSV vaccine

Read the full 307 word article

How to gain access

Continue reading with a
two-week free trial.